EE653 Cost-Effectiveness of Adjuvant Olaparib for Patients With Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Breast Cancer in Portugal
Abstract
Authors
R Sousa A Andrade S Cortesão Dias  AL Tavares